Zelda Therapeutics Ltd. announced the results of a study undertaken by a member of its Medical Advisory Board, Professor Cristina Sanchez, were recently published in the prestigious Proceedings of the National Academy of Sciences. The findings identified a new target in the endocannabinoid system for treatment of HER2+ breast cancer. The paper, entitled "Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer" was published by Professor Cristina Sanchez and her team based at the Complutense University in Madrid, Spain. The study describes a mechanism by which the cannabinoid receptor, CB2, can bind the HER2 receptor to form a novel complex. HER2 is a classic biomarker for aggressive cancer and is found in approximately 20% of breast cancer patients. The study showed that expression of CB2/HER2 receptor complexes correlates with poor prognosis in breast cancer patients. Further, treatment with tetrahydrocannbinol (THC), which binds the CB2 receptor, disrupted CB2/HER2 heteromers and promoted anti-tumour responses. Zelda's cancer focused pre-clinical research is designed to build a comprehensive data set and novel intellectual property in a form that can be licensed to third parties in the future. As part of the agreement with Professor Sanchez and the Complutense University, IP generated from the collaboration will be assigned to Zelda. This strategy complements the existing clinical trial portfolio to validate formulations and provide robust clinical evidence demanded by the medical community and regulators. Successful completion of these trials allows Zelda to quickly move towards commercialisation.